Edoxaban - Next Generation Oral Anticoagulant To Help Prevent Stroke In Patients With Atrial Fibrillation

Edoxaban, an oral factor Xa inhibitor, is currently being investigated in the pivotal phase III study ENGAGE AF-TIMI 48 (Effective aNticoaGulation with factor xA next GEneration in Atrial Fibrillation) as a potential new treatment for stroke prevention in patients with atrial fibrillation (AF). The new drug, developed solely by DAIICHI SANKYO, could offer substantial improvements over the current standard of care in thromboembolic disease. In Europe, approximately 4.